Interferon-Tau

Overview

Interferon-tau (IFN-τ) is a unique type I interferon produced by the trophoblast cells of ruminants during early pregnancy. Unlike other type I interferons (α, β), IFN-τ exhibits potent immunomodulatory and anti-inflammatory properties at doses that do not cause the fever, flu-like symptoms, or toxicity typical of IFN-α therapy. Oral IFN-τ has been investigated for autoimmune diseases including multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus, with the interesting property that mucosal (oral) administration avoids systemic toxicity while maintaining immunomodulatory efficacy.

Mechanism of Action

IFN-τ binds type I interferon receptors (IFNAR1/IFNAR2) and activates JAK1/TYK2 kinase signaling, leading to STAT1 and STAT2 phosphorylation and formation of the ISGF3 transcription factor complex that drives interferon-stimulated gene (ISG) expression. The anti-inflammatory rather than antiviral skewing of IFN-τ compared to IFN-α may relate to differential receptor binding kinetics and distinct downstream gene expression programs. Oral delivery to intestinal lymphoid tissue induces local immune tolerance programs that propagate systemically without high systemic cytokine levels.

Potential Benefits

• Immunomodulation without classical interferon toxicity
• Potential treatment for autoimmune diseases (MS, RA, lupus)
• Oral administration viable (unlike IFN-α)
• Anti-inflammatory in models of experimental autoimmune encephalomyelitis
• Reduced relapse rate in MS pilot studies

Research Dosage Notes

The following reflects doses used in published research studies. This is not medical advice.

Investigational oral dose: 90,000 IU three times weekly in MS trials.

Amino Acid Sequence

Side Effects & Safety

• Oral administration: minimal systemic effects at therapeutic doses
• Potential immune dysregulation at high doses

Synergistic Compounds

The following compounds have been studied alongside Interferon-Tau for potential complementary or synergistic effects:

Related Peptides

Learn More

References & Further Reading

• [object Object]